Top Page
Beauty Farm Medical & Health Industry, Inc.
(2373)
Beauty Farm Medical & Health Industry, Inc. (2373) vs. iShares MSCI Hong Kong ETF (EWH)
Beauty Farm Medical & Health Industry, Inc. Business Overview & Revenue Model
Beauty Farm Medical & Health Industry, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.57B | 2.15B | 1.64B | 1.78B | 1.50B |
| Gross Profit | 1.19B | 977.10M | 717.84M | 833.79M | 700.02M |
| EBITDA | 427.49M | 644.82M | 452.43M | 554.51M | 473.71M |
| Net Income | 228.46M | 215.66M | 103.11M | 193.47M | 150.96M |
Balance Sheet | |||||
| Total Assets | 4.28B | 3.30B | 2.50B | 2.48B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 1.83B | 1.57B | 910.63M | 1.08B | 801.92M |
| Total Debt | 730.59M | 563.12M | 525.50M | 515.46M | 515.69M |
| Total Liabilities | 3.30B | 2.47B | 2.29B | 2.21B | 1.96B |
| Stockholders Equity | 944.64M | 801.90M | 188.75M | 257.36M | 140.87M |
Cash Flow | |||||
| Free Cash Flow | 682.44M | 466.27M | 241.21M | 536.76M | 613.03M |
| Operating Cash Flow | 796.63M | 625.51M | 382.00M | 669.93M | 680.53M |
| Investing Cash Flow | -340.85M | -711.18M | 53.63M | -385.35M | -368.94M |
| Financing Cash Flow | -223.36M | 133.74M | -432.82M | -271.06M | -273.33M |
Beauty Farm Medical & Health Industry, Inc. Technical Analysis
Beauty Farm Medical & Health Industry, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$7.04B | 27.76 | 26.24% | 1.63% | 17.69% | 5.37% | |
72 Outperform | HK$1.75B | 5.43 | 24.13% | 4.09% | -3.85% | -19.28% | |
70 Outperform | HK$8.37B | 25.90 | 13.13% | 1.52% | 28.02% | 19.41% | |
70 Neutral | HK$9.53B | 15.05 | 9.30% | ― | 7.28% | -13.77% | |
69 Neutral | HK$8.34B | 26.55 | 2.78% | 1.96% | -1.04% | -20.43% | |
60 Neutral | HK$17.01B | 5.47 | -7.44% | 4.37% | 11.55% | -28.15% | |
42 Neutral | HK$63.51M | ― | -48.87% | ― | 3.14% | -57.92% |
Beauty Farm Medical & Health Industry, Inc. Corporate Events
Beauty Farm Medical and Health Industry Inc. announced a share repurchase of 30,000 shares at an average price of HK$29.50 per share, totaling approximately HK$885,000. The board believes the repurchase reflects confidence in the company’s long-term value and aims to enhance shareholder returns and market value.
Beauty Farm Medical & Health Industry Inc. has issued a clarification regarding its positive profit alert for the first half of 2025. The company expects to achieve a revenue of at least RMB1.45 billion, marking a growth of over 27% compared to the same period in 2024, and an adjusted net profit of no less than RMB175 million, reflecting a 33% increase. This announcement underscores the company’s strong financial performance and its positive trajectory in the market.
Beauty Farm Medical and Health Industry Inc. has announced a positive profit alert for the first half of 2025, with expected revenue of at least RMB1.45 billion, marking a 27% increase from the previous year. The company’s growth is attributed to its refined business model and dual-engine strategy, which have optimized revenue structure and increased market share, leading to a projected net profit of no less than RMB17 million, a 35% rise compared to the same period in 2024.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase, acquiring 30,000 shares at an average price of HK$29.86 each, totaling approximately HK$895,700. The board believes the current share price undervalues the company’s intrinsic worth and business prospects, and this repurchase demonstrates management’s confidence in the company’s long-term value, aiming to enhance market value and shareholder returns.
Beauty Farm Medical and Health Industry Inc. announced a voluntary on-market share repurchase of 30,500 shares at an average price of HK$28.4 per share, totaling approximately HK$866,000. The board believes this move reflects confidence in the company’s long-term value and aims to enhance its capital market value and shareholder returns.
Beauty Farm Medical & Health Industry Inc. announced that its subsidiary, Beijing Palaispa, has subscribed to principal-guaranteed wealth management products from SPD Bank, totaling RMB260 million across three transactions in 2025. These transactions, aggregated due to their similar nature and timing, constitute a discloseable transaction under the Hong Kong Stock Exchange Listing Rules, requiring notification and announcement.
Beauty Farm Medical & Health Industry Inc. announced an update regarding its final cash dividend for the year ended December 31, 2024. The dividend, amounting to HKD 0.52 per share, will be paid on September 25, 2025, following shareholder approval on June 27, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence investor sentiment positively.
Beauty Farm Medical & Health Industry Inc. has announced a revision of the annual caps for its Cooperation Framework Agreement with Guangzhou Beiminsheng, due to increasing demand. This revision, formalized through a Supplemental Cooperation Framework Agreement, aims to accommodate the operational needs of franchisee stores operated by Guangzhou Beiminsheng, reflecting the company’s strategic response to market demands and ensuring compliance with relevant listing rules.
Beauty Farm Medical & Health Industry, Inc. announced that all resolutions proposed at their Annual General Meeting on June 27, 2025, were passed by shareholders. Key resolutions included the re-election of several directors, the declaration of a final dividend, and the authorization for the board to manage directors’ remuneration and share repurchases. These decisions reflect the company’s stable governance and commitment to shareholder value, potentially strengthening its market position and investor confidence.
Beauty Farm Medical and Health Industry Inc. announced a significant change in its shareholder structure as CITIC Private Equity Funds Management Co., Ltd. (CPE) has sold approximately 21.77% of its shares, ceasing to be a substantial shareholder. This transaction involves new investors, including foreign healthcare sector funds and international hedge funds, indicating strong confidence in the company’s future growth and the overall beauty and healthcare industry in China. The board expects no adverse effects on operations due to this change.
Beauty Farm Medical & Health Industry Inc. announced an update to its final dividend for the year ended December 31, 2024. The company declared a final ordinary dividend of HKD 0.52 per share, with key dates including an ex-dividend date of August 19, 2025, and a record date of August 27, 2025. This announcement may impact shareholder expectations and company valuation as it reflects the company’s financial health and commitment to returning value to shareholders.
Beauty Farm Medical & Health Industry, Inc. has announced its upcoming annual general meeting to be held on June 27, 2025, in Shanghai. Key agenda items include the adoption of financial statements, re-election of directors, declaration of a final dividend, and the authorization for share repurchase. These resolutions aim to strengthen the company’s governance and financial position, potentially impacting shareholder value and market confidence.
Beauty Farm Medical & Health Industry Inc. announced the acquisition of an additional 20% equity interest in its subsidiary, Guangzhou Naturade, for RMB100 million, increasing its total ownership to 90%. This acquisition aims to strengthen the company’s ‘beauty and health’ ecosystem, enhance business synergy, and support long-term sustainable development.
Beauty Farm Medical & Health Industry Inc. announced that it has subscribed to principal-guaranteed wealth management products from SPD Bank, totaling RMB230 million. This strategic financial move aims to make efficient use of idle funds, with the transactions being aggregated due to their similar nature and timing, resulting in a discloseable transaction under Hong Kong’s Listing Rules.